Fléchon A - Search Results

1

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K. Loriot Y, et al. Among authors: flechon a. Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29149760 Clinical Trial.

2

High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience.

Fléchon A, Biron P, Droz JP. Fléchon A, et al. Int J Cancer. 1999 Dec 10;83(6):844-7. doi: 10.1002/(sici)1097-0215(19991210)83:6<844::aid-ijc28>3.0.co;2-6. Int J Cancer. 1999. PMID: 10597208

3

[Germ cell tumors of the testes: state of the art].

Fléchon A, Droz JP. Fléchon A, et al. Cancer Radiother. 2000 Jan-Feb;4(1):27-31. doi: 10.1016/S1278-3218(00)88649-7. Cancer Radiother. 2000. PMID: 10742806 French.

4

Intensive and timely chemotherapy, the key of success in testicular cancer.

Fléchon A, Culine S, Droz JP. Fléchon A, et al. Crit Rev Oncol Hematol. 2001 Jan;37(1):35-46. doi: 10.1016/s1040-8428(00)00074-3. Crit Rev Oncol Hematol. 2001. PMID: 11164717 Review.

5

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Fléchon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Théodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahé C. Fizazi K, et al. Among authors: flechon a. J Clin Oncol. 2001 May 15;19(10):2647-57. doi: 10.1200/JCO.2001.19.10.2647. J Clin Oncol. 2001. PMID: 11352956

6

Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors.

Fléchon A, Rivoire M, Biron P, Droz JP. Fléchon A, et al. J Urol. 2001 Jun;165(6 Pt 1):1920-6. doi: 10.1097/00005392-200106000-00019. J Urol. 2001. PMID: 11371882

7

[Is still there an indication for high-dose chemotherapy with hematopoietic stem-cell support in the treatment of germ-cell tumors?].

Fléchon A, Droz JP. Fléchon A, et al. Bull Cancer. 2001 Sep;88(9):852-7. Bull Cancer. 2001. PMID: 11604357 Free article. Review. French.

8

Pattern of relapse after first line treatment of advanced stage germ-cell tumors.

Fléchon A, Culine S, Théodore C, Droz JP. Fléchon A, et al. Eur Urol. 2005 Dec;48(6):957-63; discussion 963-4. doi: 10.1016/j.eururo.2005.06.018. Epub 2005 Jul 18. Eur Urol. 2005. PMID: 16084010

9

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area.

Piketty AC, Fléchon A, Laplanche A, Nouyrigat E, Droz JP, Théodore C, Fizazi K. Piketty AC, et al. Among authors: flechon a. Br J Cancer. 2005 Oct 17;93(8):909-14. doi: 10.1038/sj.bjc.6602791. Br J Cancer. 2005. PMID: 16205699 Free PMC article.

10

Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.

Fléchon A, Fizazi K, Gourgou-Bourgade S, Théodore C, Beuzeboc P, Geoffrois L, Mottet N, Chevreau C, Culine S. Fléchon A, et al. Anticancer Drugs. 2006 Jul;17(6):705-8. doi: 10.1097/01.cad.0000210337.85526.cc. Anticancer Drugs. 2006. PMID: 16917216

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page